^
Association details:
| Biomarker: | MET mutation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Orpathys (savolitinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell CarcinomaThe SAVOIR Phase 3 Randomized Clinical Trial
Published date:
05/29/2020
Excerpt:
Patients were adults with MET-driven (centrally confirmed), metastatic PRCC...Progression-free survival, OS, and ORR were numerically greater with savolitinib vs sunitinib….savolitinib demonstrated encouraging efficacy vs sunitinib…
DOI:
10.1001/jamaoncol.2020.2218
Trial ID:
Source:
Title:
SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).
Published date:
05/25/2020
Excerpt:
Savolitinib demonstrated encouraging efficacy and an improved safety profile over sunitinib in patients with MET-driven papillary renal cell carcinoma….In the open-label, randomized, multicenter phase 3 trial, investigators sought to assess the efficacy of savolitinib in patients with MET-driven papillary RCC versus sunitinib, a small-molecule, multitargeted receptor tyrosine kinase inhibitor.
DOI:
10.1200/JCO.2020.38.15_suppl.5002
Trial ID:
Source:
Title:
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer
Excerpt:
MET-driven PRCC was strongly associated with response; there were eight confirmed partial responders with MET-driven disease (18%)...Median progression-free survival for patients with MET-driven and MET-independent PRCC was 6.2 months (95% CI, 4.1 to 7.0 months) and 1.4 months (95% CI, 1.4 to 2.7 months), respectively (hazard ratio, 0.33; 95% CI, 0.20 to 0.52; log-rank P < .001).
DOI:
10.1200/JCO.2017.72.2967
Trial ID:
